- Home
- OPTN vs CTOR Comparison
OPTN vs CTOR Comparison
Compare OPTN & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- CTOR
- Stock Information
- Founded
- OPTN 2010
- CTOR 2021
- Country
- OPTN United States
- CTOR United States
- Employees
- OPTN N/A
- CTOR N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- CTOR
- Sector
- OPTN Health Care
- CTOR
- Exchange
- OPTN Nasdaq
- CTOR NYSE
- Market Cap
- OPTN 78.4M
- CTOR 89.9M
- IPO Year
- OPTN 2017
- CTOR N/A
- Fundamental
- Price
- OPTN $6.38
- CTOR $1.27
- Analyst Decision
- OPTN Strong Buy
- CTOR Strong Buy
- Analyst Count
- OPTN 3
- CTOR 2
- Target Price
- OPTN $16.67
- CTOR $4.50
- AVG Volume (30 Days)
- OPTN 60.7K
- CTOR 171.0K
- Earning Date
- OPTN 03-06-2025
- CTOR 02-21-2025
- Dividend Yield
- OPTN N/A
- CTOR N/A
- EPS Growth
- OPTN N/A
- CTOR N/A
- EPS
- OPTN N/A
- CTOR N/A
- Revenue
- OPTN $75,672,000.00
- CTOR N/A
- Revenue This Year
- OPTN $13.42
- CTOR N/A
- Revenue Next Year
- OPTN $38.54
- CTOR N/A
- P/E Ratio
- OPTN N/A
- CTOR N/A
- Revenue Growth
- OPTN 5.13
- CTOR N/A
- 52 Week Low
- OPTN $4.82
- CTOR $0.85
- 52 Week High
- OPTN $31.50
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- OPTN 49.78
- CTOR N/A
- Support Level
- OPTN $5.16
- CTOR N/A
- Resistance Level
- OPTN $6.97
- CTOR N/A
- Average True Range (ATR)
- OPTN 0.66
- CTOR 0.00
- MACD
- OPTN 0.10
- CTOR 0.00
- Stochastic Oscillator
- OPTN 71.08
- CTOR 0.00
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.